Angiodynamics Inc (ANGO) — SEC Filings
Angiodynamics Inc (ANGO) — 35 SEC filings. Latest: 8-K (Apr 2, 2026). Includes 17 8-K, 7 SC 13G/A, 6 10-Q.
View Angiodynamics Inc on SEC EDGAR
Overview
Angiodynamics Inc (ANGO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 2, 2026: On April 2, 2026, AngioDynamics Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes various exhibits, such as financial statements and presentations, indicating a review of the company's performance. Specific financial figures and operational details
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 32 neutral, 3 mixed. The dominant filing sentiment for Angiodynamics Inc is neutral.
Filing Type Overview
Angiodynamics Inc (ANGO) has filed 17 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of ANGO's 25 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $75.711M |
| Net Income | $(10.903)M |
| EPS | $(0.26) |
| Debt-to-Equity | N/A |
| Cash Position | $38.762M |
| Operating Margin | N/A |
| Total Assets | $265.642M |
| Total Debt | N/A |
Key Executives
- James C. Clemmer
- Michael E. Tarnoff, MD
- Lawrence T. Weiss
- Joseph B. Shea
Industry Context
AngioDynamics operates in the medical technology and device sector, which is characterized by innovation, regulatory oversight, and a focus on improving patient outcomes. The industry is competitive, with companies striving to develop minimally invasive solutions for vascular and oncological conditions. Trends include a growing demand for advanced treatment options and a shift towards value-based healthcare.
Top Tags
10-Q (5) · 8-k (4) · financial-reporting (4) · medical-devices (4) · sec-filing (4) · institutional-ownership (4) · amendment (4) · corporate-governance (3) · financial-condition (3) · regulation-fd (3)
Executive Compensation
From the most recent DEF 14A filing (Sep 25, 2025):
- Not Disclosed — CEO: $X
- Not Disclosed — Named Executive Officers: $X
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Sales | $75.711M | Increased 12.18% from $67.491M year-over-year |
| Net Loss | $(10.903)M | Improved from $(12.798)M year-over-year |
| Med Tech Sales | $35.261M | Increased 26.07% from $27.969M year-over-year |
| Med Device Sales | $40.450M | Increased 2.35% from $39.522M year-over-year |
| Operating Loss | $(10.656)M | Narrowed from $(13.098)M year-over-year |
| Cash and Cash Equivalents | $38.762M | Decreased from $55.893M at May 31, 2025 |
| Net Cash Used in Operating Activities | $(15.914)M | For the three months ended August 31, 2025 |
| Weighted Average Shares Outstanding (Basic) | 41,174 | Increased from 40,653 year-over-year |
| GAAP Revenue Decline | -3.8% | For the fiscal year ended May 31, 2025, due to divestitures and discontinuations. |
| Sales Impact from Divestitures | $33.4 million | Total impact on sales from the sale of PICCs, Midline, dialysis, BioSentry, and discontinuation of RadioFrequency Ablation and Syntrax product lines in fiscal year 2025. |
| Pro-Forma Revenue Growth | 8.1% | Excluding the impact of divested products for fiscal year 2025. |
| Med Tech Segment Revenue Growth | 19.5% | In fiscal year 2025, including Auryon, Mechanical Thrombectomy, and NanoKnife. |
| CEO's Performance-Based Compensation | 67% | Of target total compensation for fiscal year 2025, aligning executive interests with shareholders. |
| Independent Directors | 7 of 8 | Composition of the Board, indicating strong governance. |
| CEO Stock Ownership Requirement | 3 times | Valued at three times base salary, promoting alignment. |
Forward-Looking Statements
- {"claim":"The market may react positively to the updated institutional ownership, assuming the stake represents continued confidence.","entity":"AngioDynamics Inc.","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Angiodynamics Inc (ANGO)?
Angiodynamics Inc has 35 recent SEC filings from Jan 2024 to Apr 2026, including 17 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ANGO filings?
Across 35 filings, the sentiment breakdown is: 32 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Angiodynamics Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Angiodynamics Inc (ANGO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Angiodynamics Inc?
Key financial highlights from Angiodynamics Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ANGO?
The investment thesis for ANGO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Angiodynamics Inc?
Key executives identified across Angiodynamics Inc's filings include James C. Clemmer, Michael E. Tarnoff, MD, Lawrence T. Weiss, Joseph B. Shea.
What are the main risk factors for Angiodynamics Inc stock?
Of ANGO's 25 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Angiodynamics Inc?
Recent forward-looking statements from Angiodynamics Inc include guidance on {"claim":"The market may react positively to the updated institutional ownership, assuming the stake represents continue.